Article Detail - JE Part A
Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58454)- R20 - Effective October 1, 2026
Date Posted: November 5, 2026
This Billing and Coding Article has been revised under contract numbers: 01111 (CA), 01211 (AS, GU, HI, NMI), 01311 (NV), and 01911 (CA, HI & Territories).
Effective Date: Multiple dates
Summary of Changes:
Under CPT/HCPCS Codes Group 1: Codes added 0688U and 0689U. This revision is due to the 2026 Q4 CPT/HCPCS Code Update and is effective 10/01/2026.
Under Article Text subheading Additional Test-specific Indications, Limitations and Instructions revised third sentence to add "RaDaR". This revision is due to a new covered test that has successfully completed a TA and is effective 4/9/2026.
Visit the Noridian Molecular Diagnostic Services webpage to view the Active MolDX LCDs or access it via the CMS MCD.